The prevalence of muscular dystrophy and spinal muscular atrophy in Croatia: data from national and non-governmental organization registries.


Journal

Croatian medical journal
ISSN: 1332-8166
Titre abrégé: Croat Med J
Pays: Croatia
ID NLM: 9424324

Informations de publication

Date de publication:
31 Dec 2019
Historique:
entrez: 3 1 2020
pubmed: 3 1 2020
medline: 31 3 2020
Statut: ppublish

Résumé

To determine the prevalence of muscular dystrophy (MD) and spinal muscular atrophy (SMA) in Croatia by use of multiple epidemiological tools. This epidemiological study collected data from three national patient registries and one database of a non-governmental organization (NGO) of MD and SMA patients. The study involved all individuals who either had undergone hospital treatment for MD or SMA, had consulted their primary health care providers for MD- and SMA-related symptoms, were listed as disabled due to MD or SMA, or were members of the mentioned NGO in 2016. In order to prevent double entries, we created a new database of all living individuals, each with a unique identification number. The prevalence rates for 2016 were calculated by age and sex groups. There were 926 patients diagnosed with MD (544 men). Most men diagnosed with MD were in the age group 10-19, whereas most women were in the age group 50-59. MD prevalence in Croatia was 22.2 per 100000 population. There were 392 patients diagnosed with SMA (198 men). Most men with SMA were in the age group 50-59, whereas most women were in the age group 60-69. SMA prevalence in Croatia was 9.3 per 100000 population. SMA prevalence rate in Croatia is similar to SMA prevalence worldwide. However, MD prevalence rate is higher than worldwide estimates. This difference could be attributed to the fact that we could not confirm whether every patient registered in these databases actually met the diagnostic criteria for MD and SMA.

Identifiants

pubmed: 31894913
pmc: PMC6952893

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

488-493

Références

Can J Neurol Sci. 2016 Jan;43(1):163-77
pubmed: 26786644
Acta Neurol Scand. 1997 Mar;95(3):164-6
pubmed: 9088385
J Manag Care Spec Pharm. 2017 Jun;23(6):633-641
pubmed: 28530521
J Med Genet. 2016 Mar;53(3):145-51
pubmed: 26754139
Int J Appl Basic Med Res. 2019 Jul-Sep;9(3):127-128
pubmed: 31392173
BMJ Open. 2018 May 24;8(5):e020907
pubmed: 29794098
Neuroepidemiology. 2014;43(3-4):259-68
pubmed: 25532075
JAMA Pediatr. 2018 Feb 1;172(2):123-125
pubmed: 29228077
Dev Med Child Neurol. 2019 Jan;61(1):19-24
pubmed: 30221755
Orphanet J Rare Dis. 2016 May 04;11(1):58
pubmed: 27145956
Eur J Hum Genet. 2007 Jul;15(7):759-66
pubmed: 17392705
Croat Med J. 2018 Apr 30;59(2):65-70
pubmed: 29740990
Acta Myol. 2013 Dec;32(3):138-41
pubmed: 24803840

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH